Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II International Multicentre Randomised Open Label Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer

NCT00910091 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT00910091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00910091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II International Multicentre Randomised Open Label Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer
Lead sponsor
Ipsen
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2009
Completion date
July 31, 2013
Enrollment
73 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer